BELITE BIO INC - AMER

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

22 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

11 مارس 2024 22:28:39 بحسب Nasdaq GlobeNewswire

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

11 مارس 2024 21:27:47 بحسب Nasdaq GlobeNewswire

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

06 مارس 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

04 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

07 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

30 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio to Participate in the BTIG Ophthalmology Day

20 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

13 نوفمبر 2023 20:15:47 بحسب Nasdaq GlobeNewswire

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

07 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

06 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

27 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

08 أغسطس 2023 22:17:28 بحسب Nasdaq GlobeNewswire

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

04 أغسطس 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

27 يوليو 2023 17:00:00 بحسب Nasdaq GlobeNewswire

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

30 مايو 2023 20:49:26 بحسب Nasdaq GlobeNewswire

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

30 مايو 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

10 مايو 2023 19:58:59 بحسب Nasdaq GlobeNewswire

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

10 مايو 2023 15:33:22 بحسب Nasdaq GlobeNewswire

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

04 مايو 2023 11:09:06 بحسب Nasdaq GlobeNewswire